Migraine and perimenopause

Ibrahimi, Khatera; Couturier, E. G. M.; MaassenVanDenBrink, Antoinette

doi:10.1016/j.maturitas.2014.05.018

Cited by 22 publications

(14 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While the average age at menopause is approximately 51 years [2], there is significant variation around this estimate. From a clinical perspective, the likely age at menopause is used to guide decision-making regarding contraception [3, 4] assisted reproduction [5], management of menorrhagia [6], and conditions that may fluctuate with menstrual cycle hormonal variations including migraine and premenstrual dysphoric disorder [7]. Thus, markers that can assist in the prediction of menopause are of interest to women and their providers.…”

Section: Introductionmentioning

confidence: 99%

Anti-Müllerian hormone, follicle stimulating hormone, antral follicle count, and risk of menopause within 5 years

et al. 2017

View full text Add to dashboard Cite

Objective To evaluate the ability of concentration of anti-Müllerian hormone (AMH), antral follicle count (AFC), and concentration of follicle stimulating hormone (FSH) to predict the onset of menopause. Study Design The Coronary Artery Risk Development in Young Adults Study (CARDIA) Women’s Study was an ancillary study to CARDIA, a population-based study of adults aged 18–30 years followed for 3 decades. For this report, participants were women (n=426) who had attended the CARDIA year 15–16 (2000–2001) examination, had at least one ovary, were not pregnant, and underwent serum AMH and FSH measurement and transvaginal ultrasonography in 2002–2003. Main Outcome Measures The probability of menopause in 5 years based upon AMH, FSH, and AFC. Results The mean age of the women at the time of AMH, FSH, and AFC assessment was 43 years. The cumulative incidence of menopause at 25 years (or follow-up) was 27% (n=426), and the incidence within 5 years was 13% (n=55). Among women aged 45–49 years, undetectable AMH concentrations were associated with a greater than 60% probability of menopause within 5 years, whereas approximately 1/3 of women with no or just one antral follicle experienced menopause within 5 years. Both low and high concentrations of FSH were associated with greater odds of menopause than intermediate concentrations. Models with multiple markers did not improve the prediction of menopause over that afforded by models with single markers. Conclusion The ability to predict onset of menopause was improved with any of the three menopausal markers in addition to age. AMH concentrations were more closely associated with menopause than AFC or FSH.

show abstract

Section: Introductionmentioning

confidence: 99%

Anti-Müllerian hormone, follicle stimulating hormone, antral follicle count, and risk of menopause within 5 years

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The frequency of IgM seropositivity to T. gondii was higher in women with migraine than in those without this clinical feature. Migraine has been linked to perimenopause [ 14 , 15 ] as well as to T. gondii infection [ 12 ]. Therefore, it is possible that infection with T. gondii could have contributed to increasing the frequency of migraine in menopausal women.…”

Section: Discussionmentioning

confidence: 99%

“…Perimenopause is a midlife neurological transition state in women [ 13 ], and mental illnesses associated with infection with T. gondii may also occur or can be exacerbated during the perimenopausal period in women. In this regard, the incidence of migraine increases in the perimenopausal period [ 14 , 15 ], and peri- and postmenopausal women are vulnerable to the development of depression disorders [ 16 , 17 ]. Furthermore, menopausal transition is also a period of increased vulnerability to cognitive declines [ 17 ].…”

Section: Introductionmentioning

confidence: 99%

Influence of Toxoplasma gondii infection on symptoms and signs of menopause

Alvarado‐Esquivel

Sánchez‐Anguiano

Hernández‐Tinoco

et al. 2016

EuJMI

View full text Add to dashboard Cite

Some symptoms of menopause have also been described in patients with toxoplasmosis. Whether Toxoplasma gondii (T. gondii) infection has any influence on clinical manifestations of menopause is yet unknown. We sought to determine whether T. gondii exposure is associated with symptoms and signs of menopause. We performed a cross-sectional study of women attending a public health center in Durango City, Mexico. Participants were examined for the presence of anti-Toxoplasma IgG and IgM antibodies using enzyme-linked immunoassays. A questionnaire including 47 symptoms and signs potentially associated with menopause was applied. Association of seroprevalence for T. gondii with clinical characteristics of women was assessed by bivariate and multivariate analyses. Bivariate analysis showed that bouts of rapid heartbeat, breast pain, electric shock sensation, dizziness, digestive problems, low back pain, and migraine were associated with seropositivity to either IgG anti-T. gondii alone or both IgG and IgM anti-T. gondii. Breast pain was the only variable that was found to be associated with IgG seropositivity to T. gondii by multivariate analysis: (OR = 2.84; 95% CI: 1.35–5.90; P = 0.005). Our results suggest that T. gondii exposure may influence on the clinical manifestations of menopause. Results deserve further research.

show abstract

“…The more disturbing symptoms of premenstrual syndrome (physical symptoms - breast tenderness, abdominal bloating, nausea, headache, and emotional symptoms) [ 35 ] can increase in severity and duration [ 16 ]. The hormonal instability during the perimenopausal period also increases migraine incidence [ 36 ]; preexisting migraine can remain unchanged, improve, but may also worsen during perimenopause [ 37 ].…”

Section: Symptomatology Of Perimenopausementioning

confidence: 99%

Management of endometrial modifications in perimenopausal women

Nicula¹,

Costin²

2015

Medicine and Pharmacy Reports

View full text Add to dashboard Cite

Perimenopause has a variable length and time of onset and is characterized by its variability in hormonal levels. The histological changes in the perimenopausal endometrium may be represented by nonproliferative or proliferative benign or malignant lesions. A commonly encountered manifestation of endometrium lesions during menopausal transition is the abnormal uterine bleeding (AUB). The clinical management of AUB must follow a standardized classification system for optimal results. The medical and surgical treatment must be adapted according to age, risk factors, symptoms, and cycle irregularities. Use of alternative therapies and proper diet may result in improved long-term outcomes.

show abstract

Migraine and perimenopause

Cited by 22 publications

References 39 publications

Anti-Müllerian hormone, follicle stimulating hormone, antral follicle count, and risk of menopause within 5 years

Anti-Müllerian hormone, follicle stimulating hormone, antral follicle count, and risk of menopause within 5 years

Influence of Toxoplasma gondii infection on symptoms and signs of menopause

Management of endometrial modifications in perimenopausal women

Contact Info

Product

Resources

About